Axsome Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on June 5, 2020, by Axsome Therapeutics, Inc. (Nasdaq: AXSM), a Delaware corporation. The report details events occurring at the Company's 2020 Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Corporate Actions
- Board Appointment: Following the Annual Meeting, the Board appointed Mark Coleman, M.D., as the chair of the Compensation Committee, replacing Myrtle Potter, who decided not to stand for re-election.
- Director Election: Stockholders elected Mark Saad as a Class II director to serve until the 2023 annual meeting.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Voting Results
Of the 37,075,422 shares entitled to vote, 32,542,649 shares (approximately 87.8%) were represented, constituting a quorum.
| Proposal | Votes For | Votes Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Mark Saad (Class II Director) | 21,668,515 | 4,623,888 (Withheld) | N/A | 6,250,246 |
| Ratification of Ernst & Young LLP | 32,438,119 | 72,533 | 31,997 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial risks, contingencies, or unusual items. For further details on proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 21, 2020.
Key Facts for Investor Verification
- Verify the tenure and responsibilities of the newly appointed Compensation Committee Chair, Mark Coleman, M.D.
- Confirm the term end date for the newly elected Class II director, Mark Saad (2023).
- Review the April 21, 2020 Proxy Statement for detailed background on the director election and auditor ratification.
- Note that the filing indicates the Company is an emerging growth company that has elected not to use the extended transition period for new accounting standards.